Just A Life Sciences Blog...: Leerink Swann Market Perform February 5 2013 Leerink Swann Merck Downgraded

Showing posts with label Leerink Swann Market Perform February 5 2013 Leerink Swann Merck Downgraded. Show all posts

Monday, February 4, 2013

Post Earnings Call, Leerink Swann Rates Merck "Market Perform"

And that's likely the primary reason Merck is declining more than the rest of big pharma on the NYSE this morning.

Subscribe to: Posts (Atom)

Legal Stuff; Creative Commons Statement 2008-2021

Nothing written, appearing, or linked to, on this site is intended to be individual legal, or investment, advice. Consult a financial or legal adviser before making any trade, or any other decision, based anything you read, or see, on this website. This website treats all U.S. viewers' visitor-paths -- and visits -- as public data. If you are from Europe, understand that this site can see -- but will not disclose to the public -- your visitor-path, in compliance with applicable E.U. directives. We also (via enabled cookies) receive useful information about the device and software you use to access these pages, including IP address (from which location may be inferred), device type, web browser type, operating system version, phone carrier and manufacturer, member agents, application installations, device identifiers, mobile advertising identifiers, and push notification tokens. We do not sell any of this information, however -- we are not for profit, here. We automatically receive information about your interactions with these pages, such as the posts or other content you view, the searches you conduct, the people you follow, and the dates and times of your visits. We may collect (for our own use only) information using cookies, pixel tags, and similar technologies. Cookies are small text files containing a string of alphanumeric characters. We may use both session cookies and persistent cookies. A session cookie disappears after you close your browser. A persistent cookie remains after you close your browser and may be used by your browser on subsequent visits to our pages.

All material on this website is derived from public documents, and/or edited, modified, and derived from public domain sources, or in some cases, originally-created by the author(s) of this site. Any use of any proprietary image, document or other data is genuinely-intended by the author(s) to fall under the common-law "fair use" doctrine, as criticism of, and commentary on, matters of substantial public concern -- among them, the for-profit health care system in the Americas. If any person wishes to dispute this assertion of "fair use", please leave a comment in any of the comment-boxes, specifically-identifying the challenged material, and the basis for the challenge, on this site. The Site Administrator(s) will promptly consider the claim. In the same comment-box, the Site Administrator(s) will indicate the site's position on any such claim. This site is not-for-profit. Share, and share-a-like, licenses granted in, and to, all content. Copy-left 2007 through 2026.

Monday, February 4, 2013

Post Earnings Call, Leerink Swann Rates Merck "Market Perform"

Of Banksy's Brilliance...

The Sacklers, Revisited?

FDA Whistleblower [Substack]

NASA Updates

US Science History...

Of Kenosha 2020...

Women's March -- Year Two!

A Place For S-P Alums

Vioxx In the Supreme Court

CEO Hassan's $1.2B Pharmacia Role. . .

What Caused The "Bust-Up"?

Of Direct Marketing Miscues

Hassan and Cox, Part Deux?

DOCTOR Stephen Colbert!

Blog Archive

Senator Grassley's Concern

stats

The Condor. . . .

Legal Stuff; Creative Commons Statement 2008-2021

blogger.com is great!